SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES

Stefan Schreiber  1     Severine Vermeire  2     David T. Rubin  3     Silvio Danese  4, 5     Rajiv Mehta  6     Xavier Roblin  7     Paul Kwon  8     Paul van Hoek  9     Tomasz Masior  10     Rahul Barron  10     Franck-Olivier Le Brun  10     Mamoru Watanabe  11    
1 University Hospital Schleswig-Holstein, Kiel, Germany
2 UZ Leuven, Leuven, Belgium
3 University of Chicago Medicine, Chicago, United States
4 IRCCS Hospital San Raffaele, Milan, Italy
5 Vita-Salute San Raffaele University, Milan, Italy
6 Surat Institute of Digestive Sciences Hospital, Surat, India
7 University Hospital of Saint-Étienne, Saint-Étienne, France
8 Gilead Sciences Inc., Foster City, United States
9 Galapagos NV, Mechelen, Belgium
10 Galapagos GmbH, Basel, Switzerland
11 Tokyo Medical and Dental University, Tokyo, Japan

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing